Latest Breaking News On - Laura chico - Page 7 : comparemela.com

Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data

By Colin Kellaher Shares of Travere Therapeutics tumbled nearly 35% and hit a new 52-week low Tuesday after the biopharmaceutical company said a pivotal Phase 3 study of its kidney drug. | May 2, 2023

San diegoUnited statesJingming chenColin kellaherLiisa baykoEuropean medicines agencyDrug administrationTravere therapeuticsWall streetLaura chicoDow jonesNc stock exchangePress releaseIdney tvtx us89422g1076

Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data

Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesLiisa baykoColin kellaherJingming chenEuropean medicines agencyDow jones company incDrug administrationTravere therapeuticsWall streetLaura chicoDow jones

Top 10 Growth Stocks in Biotech - Insider Monkey

The biotech industry encompasses a wide range of fields, including genetic engineering, biomanufacturing, bioinformatics, and synthetic biology.

United statesUnited kingdomLaura chicoAscendis pharmaCrinetics pharmaceuticals incLineage cell therapeutics incVertex pharmaceuticals incorporatedArdelyx incRoche holdingImmunocore holdingsDrug administrationRegeneron pharmaceuticals incRecursion pharmaceuticals incRhythm pharmaceuticals incRegeneron pharmaceuticalsNasdaq biotech index

Ardelyx, Inc (NASDAQ:ARDX) Q4 2022 Earnings Call Transcript

Operator: Good afternoon everyone and welcome to the Ardelyx Fourth Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

Laura chicoMatt kaplanChris howertonPeyton bohnsackCaitlin lowieDavid rosenbaumMike raabJustin renzLaura williamsSusan rodriguezYigal nochomovitzOffice of new drugsCardiorenal advisory committeeLadenburg thalmannCorporate communicationsRegulatory affairs

StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy

Nine analysts raise stock price targets for Apellis Pharmaceuticals after it wins the FDA's first approval for a geographic atrophy therapy.

Peter steinRaymond jamesIveric bioAnnabel samimySteven seedhouseYigal nochomovitzRobertw bairdLaura chicoChris howertonChirinjeev kathuriaDoug tsaoColleen kusyTazeen ahmadJackk allenBrian culleyIb chemoprotection